Article Text

Download PDFPDF
Original article
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention
  1. Kyung Woo Park,
  2. Jeehoon Kang,
  3. Jin Joo Park,
  4. Han-Mo Yang,
  5. Hae-Young Lee,
  6. Hyun-Jae Kang,
  7. Bon-Kwon Koo,
  8. Byung-Hee Oh,
  9. Young-Bae Park,
  10. Hyo-Soo Kim
  1. Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Korea
  1. Correspondence to Professor Hyo-Soo Kim, Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, 28 Yongon-dong Chongno-gu, Seoul 110-744, Korea; hyosoo{at}


Objective To test the effect of a loss-of-function variation of the cytochrome P450 (CYP) 3A5 on drug–drug interaction between amlodipine and clopidogrel. Amlodipine is a well-known inhibitor of CYP 3A4, an isoenzyme of CYP3A that activates clopidogrel. However, controversy exists regarding whether amlodipine adversely affects clopidogrel response and clinical outcome after percutaneous coronary intervention (PCI). In the presence of CYP3A4 inhibitors such as amlodipine, the genetic variation of CYP3A5, the isoenzyme responsible for the backup CYP3A activity, may play an important role in clopidogrel activation.

Design Post hoc analysis of a prospectively enrolled cohort.

Patients Patients enrolled in the CROSS-VERIFY cohort from June 2006 to June 2010, with successful genotyping of CYP3A5.

Main outcome measures The pharmacodynamic analysis end point was clopidogrel on-treatment platelet reactivity (OPR) and the clinical analysis end point was the composite of cardiac death, non-fatal myocardial infarction, ischaemic stroke and stent thrombosis at 12 months post-PCI.

Results 1258 patients had successful genotyping and were categorised as CYP3A5 non-expressers (749 patients) and expressers (509 patients) according to the CYP3A5 genotype. Amlodipine users showed higher OPR versus non-users only in CYP3A5 non-expressers (249±83 vs 228±84 P2Y12 reaction units, p=0.013). These findings was corroborated by clinical outcomes, in which amlodipine users had a higher incidence of events compared with non-users only in CYP3A5 non-expressers (4.6% vs 0.6%, HR 7.731, CI 2.042 to 29.264, p=0.004).

Conclusions Treatment with amlodipine is associated with increased clopidogrel OPR and increased risk of thrombotic events after PCI, which is dependent on the CYP3A5 genetic status.

  • Cytochrome P450 3A enzyme
  • amlodipine
  • clopidogrel
  • on-treatment platelet reactivity
  • thrombotic event
  • coronary artery disease
  • atherosclerosis
  • molecular biology
  • restenosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea. (A102065), and a grant from the Innovative Research Institute for Cell Therapy, Seoul National University Hospital (A062260), sponsored by the Ministry of Health and Welfare, Republic of Korea.

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.